Question Number: 262
PDR Number: SQ22-000633
Date Submitted: 21/11/2022
Department or Body: Department of Health
Question 276 – Blood tests were used to measure antibody levels in COVID-19 vaccine clinical trial participants. Antibody levels are measured as the levels of antibody are indicative of vaccine efficacy.
Antibody levels are usually measured two – four weeks post vaccination in vaccine trials. Antibody levels are usually measured again three months and six months after the initial dose, to determine how long the antibody will persist in the blood and whether the antibody level will decrease after a few months.
Question 279 – No, the sensitivity of different blood types against the provisionally approved COVID-19 vaccines was not tested during clinical trials. There is not a generally accepted view among immunologists and haematologists that blood type is of any relevance in the response to vaccination.
